Oncotarget

Research Papers:

Daidzein derivative daid002 inhibits glioblastoma growth via disrupting the interaction between moesin and CD44

Xin Zhang _, Xiuting Liu, Jinghui Zhang, Wei Zhou, Jinrong Lu, Qing Wang and Rong Hu

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

DOI pending

Metrics: PDF 259 views  |   HTML 390 views  |   ?  


Abstract

Xin Zhang1, Xiuting Liu1, Jinghui Zhang1, Wei Zhou1, Jinrong Lu2, Qing Wang3 and Rong Hu1

1State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing, 210009, China

2Department of Organic Chemistry, China Pharmaceutical University, Jiangsu, Nanjing, 210009, China

3Department of Neurosurgery, Wuxi Second Hospital Affiliated Nanjing Medical University, Jiangsu, Wuxi 214002, China

Correspondence to:

Qing Wang, email: wxwqnj@hotmail.com

Rong Hu, email: ronghu@cpu.edu.cn

Keywords: glioblastoma; daid002; moesin; CD44

Received: August 29, 2017     Accepted: December 01, 2017     Published: January 11, 2018

ABSTRACT

Glioblastoma multiforme is a fatal brain tumor with very limited therapeutic options. Recently, an ezrin-radixin-moesin family protein, moesin, is reported to be positively correlated with higher grade of glioblastoma. Here, we reported that daid002, a novel daidzein derivative, inhibited glioblastoma growth and induced G0/G1 phase arrest. Daid002 decreased moesin phosphorylation through restraint of the direct interaction between moesin and CD44 on the cell membrane and reduced cyclin D1 expression via regulating nuclear translocation of β-catenin. In vivo, daid002 exerted a significant inhibition on glioblastoma growth through CD44/moesin signaling. Our findings established daid002 as an anti-glioblastoma agent by targeting CD44/moesin.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24166